SWOG clinical trial number

A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice to Increase Evidence-Based Genome Informed Therapy

Abbreviated Title
Genomic tumor board study

Eligibility Criteria Expand/Collapse

Recruitment Center Criteria:
Recruitment Centers must have completed the S2108CD Recruitment Center Application and be approved for participation in the study. See Section 5.1 of protocol for requirements.

Physician Participant Criteria:
Physician participant must be a registering investigator of the Recruitment Center that is participating in the study. If the physician is a registering investigator at more than one Recruitment Center, he/she must choose one Recruitment Center to identify with and enroll patients from; Physician participants must be board-eligible or board-certified in Medical Oncology, Gynecologic Oncology, or Neurology with certification or eligible for certification in Neuro-oncology; must be willing to offer participation in the study to all eligible patients under their care for the duration of the study; must be willing to complete all study questionnaires and, as part of the implementation objective, participate in interviews if invited; must complete all baseline questionnaires prior to registration. Physician participants at a Recruitment Center randomized to the intervention arm must be willing to participate in the educationally enhanced GTB (EGTB).

Patient Participant Criteria:
Patient participants must have a solid tumor malignancy that is either recurrent, relapsed, refractory, metastatic, or newly diagnosed Stage III or Stage IV; must be under the care of a physician enrolled on the study; must not be going on hospice care at the time of registration; may have started anti-cancer treatment for the current diagnosis. The treating physician anticipates that the patient will start a new anti-cancer treatment (either first or subsequent lines) within 6 months after registration including non-treatment studies and studies that include investigational drugs. Patients may be enrolled on genome-informed therapeutic trials, such as LungMAP, MATCH, or TAPUR; Patient participant must have a genomic tumor test (GTT) ordered prior to registration with results pending. The genomic testing may be a commercially available panel (such as FoundationOne, Caris, or Tempus) or a non-commercial tumor panel performed at an academic medical center; must be at least 18 years of age; must have a Zubrod performance status of 0-2. 4. Patient participants with tests assessing cancer-risk defining germline variants only (germline test) are not eligible.

Publication Information Expand/Collapse


Mixed-methods analysis of physician genomic confidence in the pre-implementation phase of the cluster randomized trial evaluating genomic tumor boards (SWOG S2108CD, NCT05455606)

M Trivedi;J Rueter;J Unger;K Arnold;S Colby;A Michel;A Taboada;L Graham;K Reed;J Fischer;B Symington;S Ramsey;D Hershman ASCO Quality Care Symposium (October 27-28, 2023, Boston, MA, poster; JCO Oncol Pract 19, 2023 (suppl 11; abstr 439)


Lessons from Implementing Practice-Level Cluster Randomized Studies within the NCORP Setting

K Arnold;G Anderson;D Weatherbee Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
SWOG Clinical Trial Number